Objectives: To evaluate the changes in liver stiffness measurement (LSM) in patients infected by hepatitis C virus (HCV) under pegylated interferon (Peg-IFN) plus ribavirin therapy.
Introduction
Substantial increases in overall hepatitis C virus (HCV)-related mortality rates have occurred in the past decade. 1 End-stage liver disease due to HCV infection is associated with reduced life expectancy in the short-term 2 and its treatment of choice is liver transplantation. 3 The achievement of sustained virological response (SVR) can reduce the incidence of late complications of cirrhosis and liver-related deaths. 4 -6 This benefit in clinical outcomes is probably related to the reversal of liver damage associated with chronic hepatitis C once SVR is obtained. In fact, liver inflammation and fibrosis decrease in most patients in whom SVR is achieved. 7 -10 Changes in liver histology have been assessed with sequential liver biopsies (LBs) taken before anti-HCV therapy and a few months afterwards.
7 -10 However, LB is invasive and has a number of limitations. Critical drawbacks of LB include sampling and observer variability, both of which can seriously affect histological scoring. 11 Liver stiffness measurement (LSM) by transient elastometry (TE) is a non-invasive alternative to the staging of fibrosis through LB. 12 Cirrhosis can be diagnosed with accuracy by applying TE. 12 Significant fibrosis, i.e. fibrosis extending beyond the portal tracts, can be detected and excluded without major misclassifications. 12 This technique is highly reproducible, 12 -15 in contrast with LB, which is a clear advantage for follow-up determinations. TE may not be feasible in obese patients 12 and it is inaccurate during acute liver enzyme flares. 12 Thus, TE is reliable to predict liver fibrosis in the setting of chronic hepatitis C, mainly in lean patients without intercurrent acute severe alanine aminotransferase (ALT) elevations.
Changes in LSM during pegylated interferon (Peg-IFN) plus ribavirin therapy have been evaluated in very few studies. 16, 17 In the study by Vergniol et al., 16 all of the patients who received Peg-IFN/ribavirin showed reductions in LSM, regardless of their response. In contrast, in the study by Ogawa et al., 17 SVR was related to LSM decreases during follow-up. Thus, the utility of LSM to monitor improvements in liver damage in response to Peg-IFN/ribavirin needs to be clarified and, particularly, whether SVR is related to significant reductions in LSM needs to be determined. Because of this, we evaluated the changes in LSM in patients infected by HCV under Peg-IFN/ribavirin therapy.
Patients and methods

Study population and follow-up
This was a prospective observational longitudinal study. All HCV-infected patients, with or without HIV co-infection, followed at the infectious diseases units of two tertiary care centres from southern Spain, who accomplished the following inclusion criteria were included in this study: (i) older than 18 years; (ii) started Peg-IFN/ribavirin treatment between January 2006 and June 2008; and (iii) accepted to undergo sequential LSM. Patients were excluded if LSM was not feasible due to being overweight, or other reasons, or did not fulfil the LSM validity criteria (described below). Subjects who developed acute liver enzyme elevations not explained by HCV disease were also excluded from this study.
Patients were evaluated during the anti-HCV therapy, as previously described. 18 SVR was defined as an undetectable serum HCV-RNA 24 weeks after the completion of treatment. All subjects underwent a LSM at baseline and 24 weeks after the scheduled date to end therapy, i.e. at the date of SVR assessment, regardless of the treatment response.
Treatment regimen
All individuals received Peg-IFN alfa-2a at a dose of 180 mg/week or Peg-IFN alfa-2b at a dose of 1.5 mg/kg/week plus weight-based ribavirin at a dose of 800-1200 mg/day. Programmed treatment length was 48-72 weeks in all individuals infected by HCV genotype 1 or 4. Thus, in patients without rapid virological response, defined as an HCV-RNA below the detection level at week 4, treatment was prolonged to 72 weeks if it was well tolerated and the patient agreed to do it. Individuals with HCV genotype 1 or 4 and rapid virological response were treated for 48 weeks. HCV genotype 3 carriers were treated for 24 weeks, if they were uninfected with HIV. HIV co-infected patients with genotype 2 or 3 were treated for 24 or 48 weeks, according to the criteria of the caring physician. HCV therapy was stopped when definition for non-response was fulfilled. Specifically, a patient was considered a non-responder if a reduction of ≥2 log in HCV-RNA levels was not reached at week 12 or HCV-RNA was still detectable at week 24. Dose adjustments for both drugs were carried out according to the decision of the physician that was in charge of the patient. The use of granulocyte colony-stimulating factor and erythropoietin was available for both participating centres. Growth factors were used to manage haematological adverse events, according to the criteria of the caring physician.
LSM and cut-off values to classify fibrosis TE was performed according to a standardized technique 12 by one trained operator at each participating hospital. At least 10 valid acquisitions of LSM were obtained from each patient. In order to assure validity of LSM, only those examinations with an interquartile range of ,30% of the median value of LSM and a success rate of ≥60% were considered for the analysis, according to previously proposed criteria. 12 According to data elaborated and validated using LB as reference, patients with LSM ≤6 kPa were classified as bearing mild or absent liver fibrosis (no fibrosis or fibrosis confined to the portal tracts), while those patients with LSM ≥9 kPa were considered as carriers of significant liver fibrosis (fibrosis that extends beyond the portal tracts). 19 Patients with LSM ≥14.6 kPa were classified as individuals with cirrhosis. 20 
Laboratory methods
HCV genotype was determined by line-probe assay (HCV Genotype 2.0 Assay-LIPA/Versant HCV, Siemens, Tarrytown, NY, USA). Plasma HCV-RNA load measurements were performed using a quantitative PCR assay according to the available technique [Cobas Amplicor HCV Monitor, Roche Diagnostic Systems Inc., Branchburg, NJ, USA (detection limit of 600 IU/mL); Cobas AmpliPrep-Cobas TaqMan, Roche Diagnostic Systems Inc., Meylan, France (detection limit of 50 IU/mL); or Cobas TaqMan, Roche Diagnostic Systems Inc., Pleasanton, CA, USA (detection limit of 10 IU/mL)].
Statistical analysis
The main outcome variable of the study was the difference in LSM between baseline and the scheduled date for assessing SVR. The secondary outcome variables of the study were the presence of decreases in LSM of ≥20% between the baseline and the pre-planned date of SVR evaluation, and the change in category of LSM. The associations between LSM changes and the following variables were analysed: age; gender; alcohol consumption; HCV genotype; baseline HCV viral load; HIV co-infection; ALT serum levels at baseline; type of Peg-IFN; daily dose of ribavirin; length of antiviral therapy; treatment outcome; and baseline LSM.
Continuous variables are expressed as the median (Q1-Q3). Categorical variables are expressed as the number of cases (percentage). The Student's t-test was used for comparisons between continuous variables if a normal distribution was followed and the Mann-Whitney U-test otherwise. Frequencies were compared with the x 2 test or the Fisher's test when appropriate. Comparisons of continuous repeated measures were performed with the Wilcoxon signed rank test. The variables that were associated with LSM change with a P value of ≤0.2 in univariate analyses were included in linear regression models, where the dependent variable was the LSM change from baseline to the date of SVR evaluation. Continuous variables entered in these models were log 10 -transformed. Similarly, variables with a level of association of ≤0.2 in univariate analysis with LSM decreases of ≥20% between the baseline date and the SVR evaluation date were entered in logistic regression models. The fittest models were chosen as the final model. Adjusted associations with P≤0.05 were considered significant. Data were analysed using the SPSS statistical software package release 15.0 (SPSS Inc., Chicago, IL, USA).
Ethical aspects
This study has been designed and performed according to the Helsinki declaration and was approved by the Ethics Committees of both participant hospitals.
Results
Characteristics of the study population
One hundred and seventy-eight patients met the inclusion criteria. Five (2.8%) obese individuals were excluded because LSMs were considered not valid. Two (1.1%) patients were excluded from the analysis due to acute ALT elevations related to antiretroviral treatment during the period of study.
Liver stiffness in treated HCV infection 2205 JAC One (0.6%) patient died and 27 (15%) were lost to follow-up. Thus, 143 patients (80%) were included in the analysis. Ninetyseven (68%) patients were co-infected with HIV. Among them, 93 (96%) were receiving antiretroviral therapy at the date of starting Peg-IFN/ribavirin. The main characteristics of the population are summarized in Table 1 .
Treatment outcomes
Eighty (56%) patients achieved SVR. Six (4%) subjects relapsed, 44 (31%) were non-responders and 1 (0.7%) showed breakthrough HCV viraemia. Seven (4.9%) individuals discontinued HCV treatment because of adverse events. Five (3.5%) subjects abandoned therapy. Among HCV-monoinfected individuals, SVR was achieved in 17 (59%) subjects with genotype 1 or 4 and 12 (71%) with genotype 2 or 3. Regarding HIV/HCV co-infected patients, 21 (32%) with genotype 1 or 4 and 30 (97%) with genotype 2 or 3 showed SVR. Globally, 29 (63%) HCV-monoinfected patients and 51 (53%) HIV/HCV co-infected individuals showed SVR.
Changes in LSM
The median (Q1 -Q3) LSM at baseline and at the SVR evaluation date were 8.1 (6.2 -11.6) kPa and 6.8 (5.2 -9.8) kPa (P,0.001), respectively ( Figure 1 ). The median (Q1 -Q3) decrease between both timepoints was 21 (22.75, 0.3) kPa. A decrease in LSM of ≥20% of the baseline value was observed in 56 (39%) patients at the SVR evaluation timepoint.
Among 58 patients with LSM ≥9 kPa at baseline, LSM decreased below 9 kPa in 25 (43%) of them at the SVR evaluation point. Nine (16%) of them showed reductions of LSM under 6 kPa. Ten (38%) of 26 individuals with baseline LSM ≥14.6 kPa showed decreases below 14.6 kPa at the SVR evaluation point. Six (23%) of them achieved LSM lower than 9 kPa.
Factors associated with decrease in LSM
LSM decreased significantly in patients with SVR, whereas it did not in those without SVR ( Table 2 ). The magnitude of LSM decrease was greater in patients with higher baseline LSM (Table 2 ). LSM at the SVR evaluation date was significantly lower than LSM at baseline, regardless of gender, HIV infection or baseline ALT levels (Table 2) . On the other hand, only patients with alcohol intake ,50 g/day, baseline LSM .6 kPa, treatment with Peg-IFN alfa-2a and length of HCV therapy .24 weeks showed lower LSM at the SVR assessment date than at baseline ( Table 2 ). The median (Q1 -Q3) differences between LSM at Table 3 . The difference in LSM between baseline and the SVR evaluation date was significantly greater among individuals with alcohol intake ,50 g/day, baseline ALT levels ≥100 IU/mL, baseline LSM ≥9 kPa, exposure to Peg-IFN alfa-2a, length of treatment .24 weeks and SVR (Table 3) . After multivariate analysis, baseline LSM, alcohol intake and SVR were independently associated with changes in LSM after treatment in a multiple linear regression model (Table 4) .
Decreases in LSM of ≥20% of the baseline values at the SVR evaluation date were observed in 37 (46%) patients with SVR and 19 (30%) without SVR (P ¼ 0.05) (Figure 2 ). LSM reductions of ≥20% of the baseline LSM were also associated with gender, risk group, baseline ALT levels, baseline LSM and duration of treatment (Table 5 ). In the multivariate logistic regression analysis, gender, baseline ALT levels, baseline LSM and achievement of SVR were independently associated with changes in LSM of ≥20% of the baseline levels (Table 5) . 
Discussion
In this study, we found that LSM decreases significantly among patients with chronic HCV infection who achieve SVR with Peg-IFN/ribavirin. Patients who cleared HCV infection with treatment showed a higher frequency of LSM reduction of ≥20% at the date of SVR evaluation. Thus, we suggest that sequential LSM could be used to monitor improvements in liver damage in response to anti-HCV therapy. This study has a few limitations. First, the study patients did not undergo sequential LBs before and after treatment, at the same time of LSM evaluations. LB is still the gold standard method to assess liver fibrosis. 3 In addition, LB provides data on inflammatory activity. Thus, to examine the correlation of LSM changes with liver histology changes after treatment, paired LB and LSM should ideally have been taken before and after Peg-IFN/ribavirin therapy. However, LSM is a good noninvasive surrogate marker of LB-proven fibrosis in HCV infection, both with and without HIV co-infection. 12, 19, 20 LSM is highly reproducible between trained operators 13 -15 and does not have the drawback of the variability of LB interpretation. In addition, paired LBs in patients with SVR are hardly justifiable outside clinical trials. Second, we included patients with and without HIV co-infection, who, according to HCV genotype, received different durations of treatment. This study population heterogeneity might have confounded the results. However, LSM changes were not associated with HIV co-infection. HCV genotype was also not related to LSM decrease, but longer length of Peg-IFN/ribavirin was associated with LSM reductions. The reason for this is that patients with on-treatment nonresponse stopped Peg-IFN/ribavirin earlier. Because of this, after adjustment by SVR, duration of treatment was no longer associated with LSM changes. Third, interobserver variability could have been an issue in this study, as two different observers performed LSM in each centre. However, interobserver concordance is very high for LSM, provided that operators have been trained. 13 -15 In addition, the application of LSM cut-off values to classify fibrosis does not importantly influence interobserver agreement.
14 One potential confounder of LSM changes, as a marker of fibrosis evolution, is liver inflammation. Anti-HCV treatment improves both liver fibrosis and inflammatory activity.
7 - 10 We cannot exclude that LSM decreases observed in this study were partly due to liver inflammation improvement. An increase in LSM during acute ALT flares has been reported. However, patients with acute ALT increases were excluded from the study. On the other hand, chronic liver inflammation has not been associated with LSM in multivariate analysis in other studies. 12, 21, 22 Hence, inflammatory activity does not influence pre-treatment LSM in HCV-infected patients. Further, it is not known whether reductions in liver necroinflammation after treatment may affect LSM. Patients with high baseline ALT levels experience the largest improvements in grading after anti-HCV treatment. In the present study, patients with higher baseline ALT levels showed greater changes in LSM. Because of these, multivariate models were adjusted by baseline ALT levels, so that associations with LSM changes were not confounded by this surrogate of inflammatory activity.
In the present study, we found relatively small median decreases in LSM 24 weeks after the pre-planned SVR evaluation date. With regard to these data, we should bear in mind that LSM may be very sensitive to detect subtle changes in liver fibrosis. As a continuous variable, changes in LSM are more likely to be observed than changes in the stage of fibrosis in LB, a categorical variable with a limited number of response options. This is a strength of LSM as an outcome variable. However, the clinical meaning of small variations in sequential LSM is not clear. Because of this, we also evaluated large proportional reductions in the initial LSM, specifically decreases ≥20% and changes in the classification of fibrosis, according to previously validated LSM cut-offs. Both approaches yielded similar rates of improvement. Thus, decreases ≥20% in the baseline LSM were observed in 39% of the patients. Among individuals with baseline LSM ≥9 kPa, indicative of significant fibrosis with high certainty, 19 43% of them showed reductions in the follow-up LSM to Liver stiffness in treated HCV infection ,9 kPa. In randomized clinical trials, the post-treatment LB generally is performed on the same date as was the follow-up LSM in the present study, i.e. 24 weeks after the end of treatment. The rates of improvement in fibrosis stage between paired LB, with the second LB performed on the SVR evaluation date, ranged from 26% to 35% in the Peg-IFN alfa arm of randomized clinical trials. 7 These rates of improvement are close to those observed in the herein reported study. In the current study, as well as in others, the time between paired assessments of liver damage is relatively short. Because histological normalization after HCV clearance seems a slow process, 23 particularly for cirrhosis, it may be advisable to perform follow-up LSM in the ensuing years after the end of treatment.
In the present study, LSM decreases significantly in HCV-infected patients after achieving SVR with Peg-IFN/ribavirin. This finding is in agreement with a previous report based on sequential LSM 17 and with studies on paired LB. 7, 10 We did not find any significant effect in patients without SVR, unlike other reports.
8, 16 One possible explanation is that, in the present study, a large proportion of patients without SVR were nonresponders. These patients have shown the lowest histological benefit in paired LB studies 7, 8, 10 and non-significant changes in one LSM study. 17 In conclusion, LSM decreases significantly in response to SVR achieved with Peg-IFN/ribavirin in HCV-infected patients. These improvements are not observed in patients without SVR. Sequential LSM could be used to follow changes in LSM before and after anti-HCV therapy. In the longer term, follow-up LSM could be applied to evaluate residual liver damage after HCV eradication and whether there is a trend towards normalization in LSM over time.
